Press Releases

Results from EMERALD-3, a global phase 3 clinical trial, show that adding immunotherapy alongside a commonly utilized liver-directed procedure significantly delayed cancer progression in patients whose liver cancer has spread or cannot be treated with surgery.

An oral targeted therapy is showing promise for people with dedifferentiated liposarcoma (DDLPS), a rare subtype of soft tissue sarcoma, according to Memorial Sloan Kettering Cancer Center (MSK) physician-scientists. Results from the long awaited SARC041 phase 3 clinical trial were presented today at the annual American Society of Clinical Oncology (ASCO) meeting.

Memorial Sloan Kettering Cancer Center today announced that Shakeeb Akhter has joined MSK as its new Chief Digital Officer.

Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments:Christopher D. Lima Elected 2025 AAAS Fellow Ch...

Nick Kroll, Brett Goldstein, Zarna Garg, Hasan Minhaj, Bridget Everett, and special guests took the stage for a one-night-only event, raising $2.5 million to fuel Memorial Sloan Kettering Cancer Center’s mission of ending cancer for life

Physicians and scientists from Memorial Sloan Kettering Cancer Center (MSK) will join oncology experts and members of the global cancer research community to present the latest advances in cancer discovery at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22, in San Diego, California.

Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments:Charles L. Sawyers, MD, Awarded the Harrington Prize...